3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
10
Meningioma
4
Gastro-enteropancreatic neuroendocrine tumor
3
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Glioma
2
Ependymoma
2
Adenoma, Islet Cell
2
Stomach Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hypertension
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled